Clinical Trial Update: Study Evaluating rFIX; BeneFIX® in Hemophilia B [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating BeneFIX (recombinant factor IX) for Hemophilia B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BeneFIX (recombinant coagulation factor IX concentrate)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia B | Phase 3 | Status: COMPLETED